Aims To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction.
Introduction
Aspirin demonstrates considerable clinical benefits in reducing the incidence of cardiovascular events following acute myocardial infarction [1] . The ISIS-2 study provided the first strong evidence of the therapeutic role of early aspirin treatment, with the risk of vascular death within the first 5 weeks of an acute myocardial infarction being reduced by 23% in comparison to placebo; nonfatal cardiovascular events were also significantly reduced [2] . Aspirin is a non-selective inhibitor of cyclo-oxygenase and thus prevents synthesis of thromboxane A 2 , an inducer of platelet aggregation [3] . However, aspirin does not target a number of relevant mechanisms of platelet aggregation; for example, it does not affect platelet adhesion or thrombin-or ADP-mediated platelet activation pathways. In addition, aspirin is associated with tolerability and side effect concerns, particularly an increased susceptibility to cerebral and gastrointestinal haemorrhage [4] [5] [6] [7] . There is therefore a requirement for new and more powerful antiplatelet drugs with a more favourable tolerability profile.
Triflusal (Disgren , Uriach, Spain) is an antiplatelet drug that is structurally related to aspirin but has several notable differences in its mechanism of action. Triflusal exerts multiple effects on platelet aggregation [8] . Although triflusal irreversibly blocks platelet cyclooxygenase in the same manner as aspirin [9] , it inhibits endothelial cyclooxygenase only slightly, so that prostacyclin synthesis is not significantly reduced [10] . Both triflusal and its long-lasting active metabolite, 3-hydroxy-4-trifluoro-methylbenzoic acid, inhibit degradation of platelet and endothelial cell cAMP, thereby increasing cAMP levels and blocking intracellular calcium mobilization and platelet-endothelial cell interactions [8, 11] . Triflusal and 3-hydroxy-4-trifluoromethylbenzoic acid also inhibit cyclooxygenase-2 (COX-2 ) expression, activation of the transcription factor NF-kappa B, and NF-kappa B-induced inflammatory mediators such as the vascular cell adhesion molecule 1 (VCAM-1 ) [12, 13] . In addition, triflusal increases nitric oxide synthesis in neutrophils, resulting in increased vasodilatory potential [14] . Consequently, it can be suggested that triflusal exerts its antithrombotic effect by acting on different targets involved in the platelet aggregation and vascular inflammatory processes [11] . Triflusal has demonstrated efficacy in a number of cardiovascular indications, including unstable angina [15] , peripheral vascular disease [16] , stroke [17, 18] , thromboembolic disease [19, 20] , as well as coronary angioplasty [21] and bypass surgery [22] . Clinical data suggest that triflusal may be more effective than aspirin in a number of these indications, and that haemorrhagic events may be less frequent than with aspirin [17, 19, 20, 22] . The fact that triflusal is a weaker cyclooxygenase inhibitor than aspirin may partly explain this difference [10] . The present study was undertaken to determine whether triflusal provides an efficacy advantage over aspirin in the prevention of vascular complications (death, reinfarction or cerebrovascular events) following acute myocardial infarction, and to quantify the relative safety benefits of the two drugs. The study used a sequential design, which involves continuous monitoring of clinical data until evidence for the superiority of one drug over the other is attained, or until it is concluded that a treatment difference is statistically unlikely. This design allows patient recruitment to be discontinued as soon a decision based on statistical findings can be reached.
Methods
This double-blind, randomized, sequential, parallel group study was conducted in patients with confirmed acute myocardial infarction within 24 h of onset of symptoms.
Study population
The study was carried out at 29 centres in three countries (Spain, Portugal and Italy) between February 1993 and March 1997. Inclusion and exclusion criteria are detailed in Table 1 . 
Drug treatment
Patients were randomized to receive triflusal 600 mg or aspirin 300 mg orally once daily for 35 days. Medication was administered in matched capsules to ensure study blinding and was given with the main meal. Treatment was started as soon as possible after study inclusion and within 24 h of symptom onset.
Permitted concomitant medications comprised those routinely administered following acute myocardial infarction, including thrombolytics, and these were recorded for each patient. Use of non-steroidal antiinflammatory drugs and antiplatelet or platelet-active drugs apart from the study medication was not allowed during the study period.
Efficacy and safety measurements
The primary study end-point was a composite measure reflecting death or occurrence of non-fatal myocardial infarction or non-fatal cerebrovascular events within the first 35 days after an acute myocardial infarction. The presence of any individual component of this end-point was considered as a failure of treatment.
Non-fatal reinfarction was defined as recurrence during the treatment period of signs and symptoms suggestive of acute myocardial infarction, confirmed by ECG and/or enzyme analyses within the following 72 h. A cerebrovascular event was defined as an abnormal neurological finding due to an ischaemic or haemorrhagic cerebral event, confirmed by computed tomography.
Secondary end-points were defined individually as the incidence of death, non-fatal reinfarction, non-fatal cerebrovascular events and urgent revascularization procedures occurring within the first 35 days of an acute myocardial infarction.
Drug tolerability and safety, with particular regard to bleeding events, were also assessed. Safety was assessed on the basis of spontaneously reported and solicited adverse events which were categorized according to their nature, severity, duration and outcome. In addition, tolerability was assessed using a patient questionnaire focussing on signs and symptoms known to be associated with either treatment. All adverse events identified by the questionnaire were considered to be treatment-related.
Patients were evaluated at each of three visits: at study inclusion, day 15 or discharge (whichever occurred sooner) and day 35. At study entry, acute myocardial infarction was confirmed by ECG and creatine phosphokinase assay, and patients underwent a physical examination focusing on the cardiovascular system, as well as haematological and blood biochemistry analyses and chest X-ray. The clinical history and details of the current episode were also recorded. At the second and third visits, clinical interview, physical examination and follow-up ECG were carried out, and drug efficacy, tolerability and safety were assessed.
Drug capsules were counted at the second and third visits to ascertain treatment compliance. Interruption of the study medication for d3 days was considered a protocol deviation and necessitated withdrawal of the patient.
Trial design
Estimation of patient numbers required to demonstrate a clinically relevant difference between treatments was based on findings from the ISIS-2 study, in which the combined incidence of reinfarction, cerebrovascular event or vascular death in the 5 weeks following acute myocardial infarction was 10·6% with aspirin (compared with 14·4% for controls) [2] . We assumed a 10% incidence of the primary end-point in the aspirin group, and 
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considered a 25% relative reduction in the incidence of the primary end-point to be a clinically relevant difference between treatments. The study was anticipated to have an 80% power to detect a treatment difference of this magnitude at the 5% significance level (two-tailed).
A sequential probability ratio test design with truncation at 5305 patients [23] was selected for the study. According to statistical considerations (type I and II errors and estimated risk reduction) the boundaries of the continuation region were established using Planning and Evaluating Sequential Trials software (PEST version 2.0 and 3.0) [23] [24] [25] . As the study progressed, an estimator of the accumulated difference between treatments (Z) was plotted against a measure of the accumulated information (V). If the plot of the accumulated data crossed the inner or outer boundaries of the continuation region the trial was terminated and the null hypothesis accepted or rejected, respectively.
Sequential monitoring was carried out by planned inspections of data, which were defined a priori after recruitment of the first 1000 patients and then after additional increments of 250 patients, allowing for slight deviations by calendar. A 'Christmas tree' correction of the boundary limits, allowing adjustment for discontinuous monitoring, was applied [23] .
At the end of the study, a maximum likelihood estimator ( |) of the difference between treatments was derived from the final value of (Z/V), and adjusted for bias ( x) associated with the sequential design. The secondary end-point components of the primary end-point were also adjusted. All subsequent reference to proportions and odds ratios relates to the adjusted data.
Data handling and statistical analyses
Prior to statistical analysis, data obtained at each centre were confirmed by a supervisory committee, which continuously validated all cases included in the sequential analysis as they were completed, and verified all reported end-points as soon as these were achieved.
Treatment efficacy was determined by applying the sequential approach to the validated patient population, which was defined as all correctly diagnosed and randomized patients with no exclusion criteria, who commenced the study medication within 24 h of symptom onset and for whom outcome data at day 35 were available. Results were expressed as the risk estimate of failure for the triflusal group relative to the aspirin group (odds ratio [OR] with 95% confidence interval [CI] ). For all secondary variables, hypothesis testing was carried out using the conventional Wald test (estimator/ standard error). A simulation of the sequential monitoring was performed on all randomized patients to identify the effects of any case selection bias on the primary efficacy assessment. For the purposes of this simulation, patients lost to follow-up at day 35 were considered event-free.
Tolerability and safety were quantified in terms of the relative frequency and intensity of secondary effects and adverse events in all patients who received at least one dose of study medication.
Inter-group comparisons were performed using Student's t test for quantitative variables, the Mann-Whitney U test for ordinal variables and either the Chi-squared test or Fisher's exact test for categorical variables. All analyses were two-tailed, with a significance level of 5%.
Results

Study population
Of 6615 patients screened, 4340 were not included in the study (Fig. 1) . The most frequent reasons for noneligibility were current treatment with drugs affecting platelet function, age >80 years and delay in acute myocardial infarction diagnosis >24 h from symptom onset. Inclusion criteria were fulfilled by 2275 patients, who were randomized to receive either aspirin (1140 patients) or triflusal (1135 patients). Drug safety and tolerability was assessed from the 2270 patients who received at least one dose of study medication. The supervisory committee excluded from sequential monitoring those patients with major protocol deviations (146 cases), leaving a validated population of 2124 patients that was used to determine primary and secondary study end-points. The baseline characteristics of the patient population are summarized in Tables 2 and 3 . Female patients were significantly older than male patients (mean 66·82 vs 59·52 years; P<0·0001). There were no significant differences in baseline characteristics between the two treatment groups.
A total of 441 validated patients failed to complete the 35-day treatment period for reasons other than death, the reasons being revascularization procedures (44·44%), administration of prohibited medication (14·29%), adverse events (13·15%), non-compliance (11·79%) or other causes (16·33%). No difference between treatment groups was observed in the reason for withdrawal. However, information on study end-points at day 35 was available for all validated patients.
Efficacy
Sequential monitoring stopped after the fifth sequential data inspection. At this point the study trajectory crossed the inner limit of the continuation region, permitting acceptance of the null hypothesis (no significant treatment difference) with a total of 2124 validated patients recruited to the study (Fig. 2, Table 4 ).
The primary end-point occurred in 105 of 1068 patients receiving aspirin and 99 of 1056 patients receiving triflusal, giving an adjusted OR estimate [95% CI] for treatment failure of 0·882 [0·634-1·227] (P=0·582) ( Table 5 ). The risk of non-fatal cerebrovascular events was significantly lower with triflusal than with aspirin (P=0·03). There were no significant differences between treatments in risk of death, non-fatal MI or revascularization procedures (Table 5) .
Results of analyses of data from all randomized patients were consistent with those from validated patients only; sequential monitoring would have been 
Tolerability
Adverse events possibly related to study treatment were reported in 771 patients. Considering all treatmentrelated adverse events, the most frequently affected body systems were the gastrointestinal tract (primarily dyspepsia, constipation and flatulence) and the central and peripheral nervous system, with similar incidences in both treatment groups (Table 6 ). However, triflusal was associated with a significantly lower incidence of central nervous system-associated bleeding (P=0·033), and with a non-significant trend towards less frequent bleeding in all organs (P=0·090) ( Table 6 ).
A total of 60 patients were withdrawn due to adverse events (34 patients in the aspirin group, 26 in the triflusal group). Twenty-six patients (14 in the aspirin group and 12 in the triflusal group) experienced severe adverse events that were possibly related to the study medication in terms of temporal sequence.
Discussion
The most effective means of limiting infarct size is to restore vessel patency rapidly, fully (TIMI 3 flow) and without re-occlusion. This is usually achieved through intravenous fibrinolysis and, increasingly, primary angioplasty; in all cases an anti-thrombotic regimen of anti-thrombin and antiplatelet agents is of the greatest importance. Many clinical trials have been carried out to investigate different drug combinations to enhance reperfusion, but treatment intensity has always been limited by the increased risk of haemorrhagic complications, particularly cerebral haemorrhage. Following the results of the ISIS-2 study [2] , aspirin is now widely established in such treatments. However, to date no clinical trials have been published comparing the efficacy of aspirin and other antiplatelet drugs directly in the acute stage of acute myocardial infarction.
The present study was undertaken to compare the efficacy and tolerability of triflusal vs aspirin in this setting, and showed that following an acute myocardial infarction there was no significant difference in the primary combined end-point (death, non-fatal acute myocardial infarction or non-fatal cerebrovascular events) between the triflusal and aspirin treatment groups at day 35. The adjusted proportions of end-point occurrence (9·06% for triflusal and 10·15% for aspirin) corresponded to an adjusted risk reduction of 11·8% with triflusal treatment. However, the risk of a non-fatal cerebrovascular event was 63% lower with triflusal than with aspirin (0·5% vs 1·3%). There was also no significant difference between treatment groups with regard to three of the secondary end-points: death, non-fatal acute myocardial infarction and revascularization The patient population included in the present study consisted overwhelmingly of patients experiencing their first acute myocardial infarction (94·1%), and these patients would be expected to have a lower rate of complications and a better prognosis than the typical infarct population. Indeed, a comparison of the TIM population with that of the RESCATE (Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera) study, which was specifically limited to patients presenting with first acute myocardial infarction [26] , reveals close similarities in terms of gender balance, incidence of previous cardiovascular disease and personal risk factors. Limitation of the TIM population to those patients under 80 years of age with predominantly first acute myocardial infarction provides for greater homogeneity and might be expected to improve the accuracy of excess risk estimates.
The safety and tolerability of both drugs was good: only 2·64% of patients withdrew from the study due to adverse events, and the incidence of severe adverse events was low. The most frequently reported adverse events were those affecting the gastrointestinal and central and peripheral nervous systems, a finding possibly attributable in part to the use of a questionnaire focusing on these known adverse effects. The incidence of adverse bleeding events related to the central nervous system was over three-fold greater with aspirin than with triflusal, and there were fewer bleeding events in all other body systems with triflusal than with aspirin.
A feature of sequential clinical trial design is close and rigorous monitoring of patient data on a continual basis. This has the advantage of allowing study termination as soon as sufficient information has been gathered to permit a statistically based conclusion on treatment outcome. The current study fulfilled the recommended criteria for adoption of a sequential design: a large sample size (sample size required by classical approach: 4170 patients), gradual recruitment of patients over a long period of time, a single and well-defined primary efficacy measure, and a short follow-up period for each patient. This design has proved useful in the present study, as reflected by the fact that the trial was terminated after recruiting 2124 validated patients. As confirmation of the absence of bias in the patient selection procedure, a simulated sequential analysis of all randomized patients showed that the study would have been stopped at the same point under a strict intent-totreat approach.
Conclusions
The TIM study shows that treatment with triflusal in the acute phase of myocardial infarction has a similar efficacy to aspirin in the prevention of cardiovascular events (death, non-fatal myocardial infarction or nonfatal cerebrovascular event). However, triflusal is associated with a significantly lower incidence of non-fatal cerebrovascular events and cerebral haemorrhage. Triflusal currently appears to constitute a valid alternative to aspirin in the acute phase of acute myocardial infarction, particularly in patients at increased risk of stroke or haemorrhage. 
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